Skip to content
ClinCalc Pro
Menu
Positive inotrope (beta-1 agonist) Pregnancy: There are no adequate data on the safety of dobutamine in human pregnancy and it is not known whether it crosses the placenta; dobutamine should not be used during pregnancy unless the potential benefits outweigh the potential risks to the foetus and there are no safer therapeutic alternatives. Breastfeeding: excretion in breast milk is unknown - exercise caution; if treatment is required, breast feeding should be discontinued for its duration.

Dobutamine

Brand names: Dobutamine Injection

Dobutamine is an intravenous inotropic sympathomimetic used for short-term cardiac support in acute heart failure and low cardiac output states.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 2.5-10 micrograms dobutamine/kg/min - the majority of patients respond to this range; in individual cases doses up to 40 micrograms dobutamine/kg/min have been administered. Doses must be individually adjusted, the required infusion rate depending on the patient's response to therapy and the adverse reactions experienced
Route: Intravenous infusion only - the concentrate must be diluted before administration (e.g. with 5% glucose, 0.9% sodium chloride, or 0.45% sodium chloride in 5% glucose) and given as a continuous infusion because of dobutamine's short half-life
Frequency: Continuous intravenous infusion, titrated to response; the dose should be gradually reduced when discontinuing therapy
Max: The SPC states no formal ceiling for inotropic support: 'In individual cases, doses up to 40 micrograms dobutamine/kg/min have been administered'
SOURCE: UK SPC (eMC) for Dobutamine 12.5 mg/ml concentrate for solution for infusion, §4.2 (https://www.medicines.org.uk/emc/product/100017/smpc). The SPC writes the unit as micrograms/kg/min (ug/kg/min) - NOT mg/kg. WORKED INFUSION RATES from the SPC: one ampoule (250 mg in 20 ml) diluted to 500 ml (final concentration 0.5 mg/ml) gives, at 2.5/5/10 micrograms/kg/min respectively, 15/30/60 ml/h for a 50 kg patient, 21/42/84 ml/h for 70 kg and 27/54/108 ml/h for 90 kg; if the concentration is doubled (500 mg in 500 ml, or 250 mg in 250 ml), halve the infusion rates. By syringe pump, one ampoule diluted to 50 ml (final concentration 5 mg/ml) gives 1.5/3.0/6.0 ml/h at 50 kg, 2.1/4.2/8.4 ml/h at 70 kg and 2.7/5.4/10.8 ml/h at 90 kg for 2.5/5/10 micrograms/kg/min. MONITORING: heart rate, heart rhythm, blood pressure, diuresis and infusion rate should be closely monitored; cardiac output, CVP and pulmonary capillary pressure if possible. Duration should be as short as clinically possible; if given continuously for more than 72 hours, tolerance (tachyphylaxis) may occur, requiring a dose increase. Hypovolaemia should be corrected before administering dobutamine. Incompatible with bicarbonate and other strong alkaline solutions. DOBUTAMINE STRESS ECHOCARDIOGRAPHY (adults only, separate indication with its own contraindications): the most frequently applied scheme starts at 5 micrograms/kg/min, increased every 3 minutes to 10, 20, 30, 40 micrograms/kg/min until a diagnostic endpoint is reached; if no endpoint is reached, atropine sulfate 0.5 to 2 mg may be given in divided doses of 0.25-0.5 mg at 1-minute intervals to increase heart rate, or alternatively the dobutamine infusion rate may be increased to 50 micrograms/kg/min - to be undertaken only by a physician experienced in cardiology stress testing, with continuous echocardiographic/ECG/BP monitoring and resuscitation facilities. §4.5 was not present in the fetched bundle, so no interaction list is given.

Paediatric dose

Dose: 5 micrograms/kg/minute/kg
Route: Continuous intravenous infusion via an infusion pump; dilute to 0.5-1 mg/ml (maximum 5 mg/ml if fluid restricted) with glucose 5% or sodium chloride 0.9%; infuse higher-concentration solutions through a central venous catheter only
Frequency: Continuous infusion, titrated to clinical response
Max: Adjust according to clinical response within the range 2-20 micrograms/kg/minute; most adverse reactions (particularly tachycardia) were seen at doses of 7.5 micrograms/kg/minute or above
SPC §4.2: for all paediatric age groups (neonates to 18 years) an INITIAL dose of 5 micrograms/kg/minute, adjusted according to clinical response to 2-20 micrograms/kg/minute, is recommended (unit is micrograms/kg/MINUTE - not mg/kg). Occasionally a dose as low as 0.5-1.0 micrograms/kg/minute will produce a response. The minimum effective dose in children is believed to be higher than in adults, while the maximum tolerated dose is believed to be lower - use caution with high doses. Response varies greatly between paediatric patients, so the dose cannot be determined a priori and must be titrated. Reducing or stopping the infusion is usually all that is required for rapid reversal of undesirable effects. NEONATAL INTENSIVE CARE (SPC method of administration): dilute 30 mg/kg body weight to a final volume of 50 ml of infusion fluid - an infusion rate of 0.5 ml/hour then provides a dose of 5 micrograms/kg/minute. Increments in heart rate and blood pressure appear more frequent and intense in children; pulmonary wedge pressure may not fall as it does in adults and may rise, especially in infants under one year. Dobutamine stress echocardiography is for the adult population only. Verify against a children's formulary.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

SPC §4.2: for all paediatric age groups (neonates to 18 years) an INITIAL dose of 5 micrograms/kg/minute, adjusted according to clinical response to 2-20 micrograms/kg/minute, is recommended (unit is micrograms/kg/MINUTE - not mg/kg). Occasionally a dose as low as 0.5-1.0 micrograms/kg/minute will produce a response. The minimum effective dose in children is believed to be higher than in adults, while the maximum tolerated dose is believed to be lower - use caution with high doses. Response varies greatly between paediatric patients, so the dose cannot be determined a priori and must be titrated. Reducing or stopping the infusion is usually all that is required for rapid reversal of undesirable effects. NEONATAL INTENSIVE CARE (SPC method of administration): dilute 30 mg/kg body weight to a final volume of 50 ml of infusion fluid - an infusion rate of 0.5 ml/hour then provides a dose of 5 micrograms/kg/minute. Increments in heart rate and blood pressure appear more frequent and intense in children; pulmonary wedge pressure may not fall as it does in adults and may rise, especially in infants under one year. Dobutamine stress echocardiography is for the adult population only. Verify against a children's formulary.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to dobutamine or to any of the excipients, including patients with bronchial asthma who are hypersensitive to sulfites (sodium metabisulfite)
  • Mechanical obstruction of ventricular filling and/or outflow - e.g. pericardial tamponade, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, severe aortic stenosis
  • Hypovolaemic conditions
  • Phaeochromocytoma
  • Additionally for stress echocardiography: recent myocardial infarction (within the last 30 days), unstable angina, left main stem stenosis, haemodynamically significant LV outflow obstruction or valvular defect, severe heart failure (NYHA III-IV), predisposition to or history of clinically significant/chronic arrhythmia (particularly recurrent persistent VT), significant conduction disturbance, acute pericarditis/myocarditis/endocarditis, aortic dissection or aneurysm, poor sonographic imaging conditions, inadequately controlled arterial hypertension

Side effects

  • Very common: increase in heart rate of 30 beats/min or more, and blood pressure increase of 50 mmHg or more (greater rises in patients with arterial hypertension)
  • Common: blood pressure decrease, ventricular dysrhythmia and dose-dependent ventricular extrasystoles; increased ventricular rate in atrial fibrillation (digitalise before infusion)
  • Common: anginal pain and palpitations; vasoconstriction, particularly in patients previously treated with beta blockers
  • Common: headache, nausea, bronchospasm, shortness of breath, exanthema, eosinophilia and inhibition of thrombocyte aggregation (with infusion over several days)
  • Uncommon/rare: hypersensitivity reactions including rash and eosinophilic myocarditis; sulfite-related allergic reactions including anaphylaxis; ventricular tachycardia, ventricular fibrillation, atrial fibrillation; very rarely bradycardia, myocardial ischaemia, myocardial infarction, cardiac arrest and hypokalaemia

Clinical monograph

How it works

It acts predominantly on beta-1 adrenergic receptors to increase myocardial contractility and cardiac output, with relatively modest effects on heart rate at usual infusion rates.

Prescribing in practice

  • Correct hypovolaemia before starting, and give by controlled infusion with continuous cardiac and blood-pressure monitoring as it can provoke tachyarrhythmias and ischaemia.
  • Use with caution in significant outflow obstruction and in atrial fibrillation, where it may increase ventricular rate.
  • Titrate to clinical and haemodynamic response and avoid abrupt large changes in infusion rate.

Monitoring

Monitor continuous ECG, blood pressure, heart rate and, where available, cardiac output and urine output throughout the infusion.

Counselling the patient

  • Explain to the patient that this medicine supports the heart's pumping and is given as a closely monitored drip.
  • Advise reporting palpitations or chest discomfort to staff immediately.
  • Reassure that the dose is adjusted to their response and stopped gradually.

Evidence & guidelines

Dobutamine is a standard agent for short-term inotropic support in low cardiac output states and is widely used in critical care.

Reference: ESC Cardiogenic Shock Guidelines; NICE NG106; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

Dobutamine is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.